ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1461

The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis

Omer Pamuk1 and Sarfaraz Hasni2, 1NIH/NIAMS, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD

Meeting: ACR Convergence 2022

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus erythematosus (SLE). Thrombocytopenia is also frequently present in SLE patients and has been associated with poor prognosis. Recent population-based cohort studies suggest that the incidence of SLE is increased in ITP patients and that isolated ITP with a positive Anti-nuclear antibody (ANA) may be at much higher risk of developing SAD. In this study, we performed a meta-analysis to evaluate the development of SLE in patients with ITP.

Methods: Literature search was performed by using terms ‘immune thrombocytopenia’, ‘antinuclear antibody’ and ‘systemic lupus erythematosus’ in PubMed, Web of Science and Cochrane Library without any restrictions prior to May 2022. Studies were included that reported development of SLE in ITP patients. Forest plot was used to detect overall SLE frequency in ITP and compare risk ratios for SLE development in different ITP subgroups. In addition, we also evaluated childhood-onset (≤16 years).

Results: 26 eligible studies comprising 14895 ITP patients were included in analysis. 307 ITP patients developed SLE during the follow-up period (range: 1.1- 14 years) (2.06%, 95%CI: 1.8-2.3%) (Figure 1). The rates of SLE in aITP and cITP cases were not significantly different, 2.02% (95%CI: 1-4%) and 2.4 (95%CI: 1.7-3.3%) respectively. Relative risk (RR) for developing SLE was significantly higher in female ITP patients (RR: 4.93, 95%CI: 3.33-7.29, p< 0.001) (Figure 2). ANA was reported in 21 studies that included 3772 ITP patients (3176 ANA negative ITP, 596 ANA positive ITP {15.5%}). There was significantly increased risk of SLE development (RR: 35.07, 95%CI: 18.66-65.9, p< 0.001) in ANA positive patients (Figure 3). cITP patients had higher RR for SLE development than aITP patients, however, the difference was not significant (RR-cITP: 74.93, 95%CI: 22.83-245.99, RR-aITP: 25.56 (95%CI: 11.76-55.49).

Conclusion: We identified ITP patients at higher risk of developing SLE in future. Pooled data revealed that positive ANA (present in 15.5%) and females are at significantly higher risk of developing SLE. Although the difference was not statistically significant, but SLE was more common in cITP patients.

Supporting image 1

Figure 1. Forest plot of the meta-analysis of risk of SLE among patients with ITP.

Supporting image 2

Figure 2. Forest plot of the meta-analysis of SLE risk in female and male ITP patients.

Supporting image 3

Figure 3. Forest plot of the relative risk ratios of SLE development in ITP patients with ANA positivity.


Disclosures: O. Pamuk, None; S. Hasni, None.

To cite this abstract in AMA style:

Pamuk O, Hasni S. The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-frequency-of-systemic-lupus-erythematosus-in-patients-with-immune-thrombocytopenic-purpura-a-systematic-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-frequency-of-systemic-lupus-erythematosus-in-patients-with-immune-thrombocytopenic-purpura-a-systematic-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology